p 110

P110 heptapeptide is a specific peptide inhibitor that interacts with Drp1/Fis1 (IC₅₀=1.8 μM). By competitively blocking the binding of Drp1 to Fis1, P110 heptapeptide inhibits pathological mitochondrial fission while preserving the physiological function of Drp1, thereby reducing pathological features in numerous models of neurodegeneration, ischemia, and sepsis. P110 heptapeptide exhibits neuroprotective, anti-inflammatory, and anti-sepsis activity and can be used in research on neurodegenerative diseases and conditions associated with mitochondrial dysfunction.

TAT-P110 is a peptide inhibitor that disrupts the interaction between Drp1 and Fis1, effectively reducing pathological changes in various models of neurodegenerative diseases, ischemia, and sepsis without impairing the physiological function of Drp1.

P110 TFA is a dynamin-related protein 1 (Drp1) inhibitor, inhibits Drp1 GTPase activity.

Compound P110 (Drp1 peptide inhibitor P110) is a selective Drp1 peptide inhibitor with neuroprotective effects. It inhibits the activation of Drp1, prevents Drp1 mitochondrial translocation induced by MPTP, and alleviates dopamine neuron loss, dopaminergic terminal damage, and behavioral deficits caused by MPTP. This compound is useful for Alzheimer's disease research. Additionally, Compound P110 reduces mitochondrial and organ damage in animal models of Huntington's disease, cerebral ischemia, and myocardial infarction.

Drp1 peptide inhibitor P110 (Compound P110) TFA is a selective Drp1 peptide inhibitor with neuroprotective properties. It suppresses the activation of Drp1, prevents Drp1 mitochondrial translocation induced by MPTP, and reduces MPTP-induced loss of dopaminergic neurons, damage to dopaminergic nerve terminals, and behavioral defects, making it useful for Alzheimer's disease research. Furthermore, Drp1 peptide inhibitor P110 TFA mitigates mitochondrial and organ damage in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction.

CD36 Peptide P (93-110), Cys conjugated, a Cys-labelled CD36 Peptide, blocks the binding of CD36 to immobilized thrombospondin and partially inhibits collagen-induced platelet aggregation [1].

GPR110 peptide agonist P12 is a peptide that acts as an agonist for GPR110. This compound markedly enhances the initial rate of G protein GTPγS binding stimulated by GPR110. It mimics the action of the natural ligand, causing the extracellular domain (ECD) of GPR110 to dissociate from the seven-transmembrane domain (7TM) and exposing the N-terminal β-strand-13/stalk region of the 7TM domain, which acts as the agonist activating G protein signaling. GPR110 peptide agonist P12 is applicable in research related to developmental disorders and cancers associated with GPR110.

GPR110 peptide agonist P12 acetate is an acetate form of GPR110 peptide agonist P12 and acts as a potent agonist for GPR110. This peptide significantly enhances the initial rate of G protein GTPγS binding stimulated by GPR110. By mimicking the action of natural ligands, GPR110 peptide agonist P12 acetate causes the extracellular domain (ECD) of GPR110 to dissociate from the seven transmembrane domain (7TM), revealing the N-terminal β-strand-13/stalk region of the 7TM domain, which facilitates the activation of G protein signaling. This compound is utilized in research related to developmental disorders and cancers associated with GPR110.

DQP 1105 is a NMDA receptor antagonist.

LY294002 (SF 1101) is a broad-spectrum inhibitor of PI3K, inhibiting PI3Kα, PI3Kδ, and PI3Kβ (IC50=0.5/0.57/0.97 μM). LY294002 is also an inhibitor of DNA-PK (IC50=1.4 μM) and an inhibitor of CK2 (IC50=98 nM). LY294002 activates apoptosis and autophagy.

Alpelisib (BYL-719) is a PI3Kα inhibitor (IC50=5 nM) with selective, potent, and oral activity, inhibiting PI3Kβ/γ/δ with low activity (IC50=250/290/1200 nM). Alpelisib demonstrates antitumor activity and specifically targets PIK3CA mutant tumors.

Duvelisib (INK1197, IPI-145) is a selective inhibitor of phosphatidylinositol 3-kinase (PI3K) and p100δ, with effects on p110δ (IC50 value is 0.0025 μM), p110γ (IC50 value is 0.274 μM), p110β (IC50 value is 0.85 μM) and p110α (IC50 value is 1.602 μM).

TGX-115 is a cell-permeable and potent inhibitor of the PI 3-K isoform p110β/p110δ (IC50 values of 0.13 μM for p110β and 0.63 μM for p110δ), an enzyme that regulates platelet adhesion and inhibits phosphoinositide (PI) 3-kinase, and can be used to treat coronary artery occlusion, stroke, acute coronary artery It can be used to treat cardiovascular diseases such as coronary occlusion, stroke, acute coronary syndrome, acute myocardial infarction, restenosis, atherosclerosis and unstable angina.

Idelalisib (GS-1101) is a small molecule inhibitor of the PI3K catalytic subunit p110δ (IC50: 2.5 nM). The selectivity for p110δ is 40- to 300-fold than p110α/β/γ.

PI-3065 is a novel potent and selective PI3K p110δ inhibitor.

Acalisib (CAL-120) (GS-9820) is a potent and selective inhibitor of PI3Kδ.

Melanin Concentrating Hormone, salmon acetate (MCH (salmon)) is a 19 amino acid cyclic peptide, is largely expressed in the hypothalamus.

ETP-46321 is an effective and orally bioavailable PI3Kα/PI3Kδ inhibitor (Ki: 2.3/14.2 nM).

CAL-130 is a PI3Kδ and PI3Kγ inhibitor [IC50s: 1.3 and 6.1 nM].

CAL-130 Hydrochloride is a PI3Kδ and PI3Kγ inhibitor (IC50s: 1.3 and 6.1 nM).

Pictilisib dimethanesulfonate (GDC-0941 2 MeSO3H salt) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).

Idelalisib-D5, a version of Idelalisib (T8651) marked with deuterium, is an orally bioavailable and highly selective inhibitor of p110δ.

Zandelisib is an inhibitor of phosphatidylinositol 3-kinase (PI3K)(p110δ, IC50 of 3.5 nM), and with antineoplastic activity.

Dactolisib Tosylate (BEZ235 Tosylate) is a dual kinase inhibitor targeting PI3K and mTOR, with IC50 values of 4, 75, 7, and 5 nM for PI3Kα, β, γ, and δ, respectively. It also inhibits mTORC1 and mTORC2.